 |
Consolidated Statements of Cash Flows
Mitsubishi Pharma Corporation and Consolidated Subsidiaries |
|
|
| Years ended March 31, 2006 and 2005 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Millions of yen |
|
Thousands of
U.S. dollars
(Note 3) |
|
|
 |
|
|
|
2006 |
|
2005 |
|
2006 |
|
| Cash flows from operating activities |
| Income before income taxes and minority interests |
|
|
|
¥ |
34,471 |
|
|
¥ |
24,394 |
|
|
$ |
294,624 |
|
| Adjustments to reconcile income before income taxes and |
| minority interests to net cash provided by operating activities: |
| Depreciation and amortization |
|
|
|
|
11,796 |
|
|
|
11,457 |
|
|
|
100,821 |
|
| Loss on impairment of fixed assets |
|
|
|
|
333 |
|
|
|
3,535 |
|
|
|
2,846 |
|
| Decrease in accrued retirement benefits |
|
|
|
|
(1,998 |
) |
|
|
(6,620 |
) |
|
|
(17,077 |
) |
| Interest and dividend income |
|
|
|
|
(263 |
) |
|
|
(186 |
) |
|
|
(2,248 |
) |
|
|
|
|
174 |
|
|
|
286 |
|
|
|
1,487 |
|
| Equity in losses of unconsolidated subsidiaries |
|
|
|
|
81 |
|
|
|
315 |
|
|
|
692 |
|
| Gain on sales of investments in securities |
|
|
|
|
(605 |
) |
|
|
(260 |
) |
|
|
(5,171 |
) |
| Gain on sales of property, plant and equipment |
|
|
|
|
(1,322 |
) |
|
|
(1,595 |
) |
|
|
(11,299 |
) |
| Loss on disposal of property, plant and equipment |
|
|
|
|
189 |
|
|
|
302 |
|
|
|
1,615 |
|
|
|
|
|
(366 |
) |
|
|
(49 |
) |
|
|
(3,128 |
) |
| Changes in operating assets and liabilities: |
| Notes and accounts receivable, trade |
|
|
|
|
7,870 |
|
|
|
4,111 |
|
|
|
67,265 |
|
|
|
|
|
1,639 |
|
|
|
1,689 |
|
|
|
14,009 |
|
| Notes and accounts payable, trade |
|
|
|
|
1,059 |
|
|
|
1,411 |
|
|
|
9,051 |
|
| Consumption taxes payable |
|
|
|
|
101 |
|
|
|
(116 |
) |
|
|
863 |
|
|
|
|
|
(5,607 |
) |
|
|
656 |
|
|
|
(47,923 |
) |
|
|
|
|
|
|
|
|
|
|
47,552 |
|
|
|
39,330 |
|
|
|
406,427 |
|
| Interest and dividends received |
|
|
|
|
258 |
|
|
|
186 |
|
|
|
2,205 |
|
|
|
|
|
(181 |
) |
|
|
(292 |
) |
|
|
(1,547 |
) |
|
|
|
|
(10,600 |
) |
|
|
(11,791 |
) |
|
|
(90,598 |
) |
|
|
|
|
|
|
| Net cash provided by operating activities |
|
|
|
|
37,029 |
|
|
|
27,433 |
|
|
|
316,487 |
|
| |
| Cash flows from investing activities |
| Increase in time deposits |
|
|
|
|
(1,000 |
) |
|
|
|
|
|
|
(8,547 |
) |
| Decrease in time deposits |
|
|
|
|
|
|
|
|
5 |
|
|
|
|
|
| Purchases of property, plant and equipment |
|
|
|
|
(11,804 |
) |
|
|
(10,483 |
) |
|
|
(100,889 |
) |
| Proceeds from sales of property, plant and equipment |
|
|
|
|
2,691 |
|
|
|
4,264 |
|
|
|
23,000 |
|
| Proceeds from sales of investments in securities |
|
|
|
|
1,427 |
|
|
|
829 |
|
|
|
12,197 |
|
| Purchases of investments in securities |
|
|
|
|
(969 |
) |
|
|
(26 |
) |
|
|
(8,282 |
) |
|
|
|
|
(217 |
) |
|
|
(1,539 |
) |
|
|
(1,855 |
) |
|
|
|
|
|
|
| Net cash used in investing activities |
|
|
|
|
(9,872 |
) |
|
|
(6,950 |
) |
|
|
(84,376 |
) |
| |
| Cash flows from financing activities |
| Decrease in short-term loans, net |
|
|
|
|
(979 |
) |
|
|
(260 |
) |
|
|
(8,367 |
) |
| Repayment of long-term debt |
|
|
|
|
(1,396 |
) |
|
|
(5,347 |
) |
|
|
(11,932 |
) |
|
|
|
|
(4,525 |
) |
|
|
(4,533 |
) |
|
|
(38,675 |
) |
| Cash dividends paid to minority interests |
|
|
|
|
(634 |
) |
|
|
(43 |
) |
|
|
(5,419 |
) |
|
|
|
|
(278 |
) |
|
|
(403 |
) |
|
|
(2,376 |
) |
|
|
|
|
|
|
| Net cash used in financing activities |
|
|
|
|
(7,812 |
) |
|
|
(10,586 |
) |
|
|
(66,769 |
) |
| |
| Effect of exchange rate changes on cash and cash equivalents |
|
|
|
|
307 |
|
|
|
99 |
|
|
|
2,624 |
|
|
|
|
|
|
|
| Increase in cash and cash equivalents |
|
|
|
|
19,652 |
|
|
|
9,996 |
|
|
|
167,966 |
|
| Cash and cash equivalents at beginning of year |
|
|
|
|
44,192 |
|
|
|
34,196 |
|
|
|
377,710 |
|
| Increase in cash and cash equivalents resulting |
| from inclusion of a consolidated subsidiary |
|
|
|
|
13 |
|
|
|
|
|
|
|
111 |
|
| Decrease in cash and cash equivalents resulting |
| from exclusion of consolidated subsidiaries |
|
|
|
|
(45 |
) |
|
|
|
|
|
|
(385 |
) |
|
|
|
|
|
|
| Cash and cash equivalents at end of year (Note 16) |
|
|
|
¥ |
63,812 |
|
|
¥ |
44,192 |
|
|
$ |
545,402 |
|
|
 |
|
|
|
|
|
|
|
| See accompanying notes to consolidated financial statements. |
|
|
|
